期刊文献+

非心脏术后低氧性呼衰患者经鼻高流量氧疗失败危险因素及早期预警模型 被引量:4

Analysis of risk factors associated with failure of nasal high-flow oxygen therapy in hypoxic respiratory failure patients after non-cardiac surgery
下载PDF
导出
摘要 目的分析非心脏术后低氧性呼衰患者接受经鼻高流量氧疗(HFNC)治疗失败的早期危险因素。方法回顾分析北京大学人民医院2016年1月至2019年12月接受HFNC治疗并符合标准的患者资料,探索HFNC失败的心脏及非心脏危险因素并建立早期预警模型。结果共纳入患者133例,根据HFNC失败标准分为HFNC失败组(n=40)和成功组(n=93)。多因素分析显示,治疗初期高急性生理与慢性健康状况评分Ⅱ(APACHⅡ)、发热、高心肌肌钙蛋白I(TNI)及治疗1 h后ROX(SpO_2/FiO_2/RR)<8是HFNC失败的独立危险因素;建立回归模型Y=-2.158+1.882×发热+0.283×APACHII-0.326×ROX+2.222×TNI,模型ROC曲线下面积(AUC)为0.915。结论非心脏术后低氧性呼衰患者应用HFNC,基础高APACHⅡ评分及TNI、发热,提示治疗失败风险较高,应谨慎选择,治疗1 h后ROX仍较低,应及时调整治疗策略。 Objective To investigate the risk factors associated with failure of nasal high-flow nasal oxygen therapy(HFNC)in hypoxic respiratory failure patients after non-cardiac surgery.Methods This retrospective study was conducted at Peking University People′s Hospital.The subjects included all patients who suffering hypoxic respiratory failure after non-cardiac surgery from January 2016 to December 2019.Clinical and laboratory parameters use statistical methods to explore the risk factors involved in HFNC failure and establish an early warning model.Results A total of 133 patients were included.According to HFNC failure criteria,patients were divided into HFNC failure group(n=40)and success group(n=93).Multivariate analysis showed that patient with temperature(T)>37.3℃,high acute physiology and chronic health status scoreⅡ(APACHⅡ)score,cardiac troponinⅠ(TNI)level before using HFNC,and low ROX(SpO2/FiO2/RR)<8 at 1 hour after treatment were independent risk factors for HFNC failure;a regression model was established:Y=-2.158+1.882×fever+0.283×APACHⅡ-0.326×ROX+2.222×TNI,the area under the ROC curve(AUC)of the model is 0.915(P<0.01).Conclusions Hypoxic respiratory failure patients after non-cardiac surgery fever,High APACHII score and TNI level at baseline are indicate a higher risk of HFNC failure.ROX is still lower after 1 h treatment an important indicator for further mechanical ventilation,the treatment strategy should be adjusted in time.
作者 杜安琪 李纾 吕姗 赵连泽 安友仲 DU Anqi;LI Shu;LV Shan;ZHAO Lianze;AN Youzhong(Department cf Critical Care Medicine,Peking University Peoples Hospital,Beijing 100044,China)
出处 《实用医学杂志》 CAS 北大核心 2021年第7期914-918,共5页 The Journal of Practical Medicine
基金 首都卫生发展科研专项资助项目(编号:首发2016-4-4084)。
关键词 经鼻高流量氧疗 非心脏术后 低氧型呼衰 失败 危险因素 High-flow nasal cannula oxygen therapy non-cardiac surgery hypoxic respiratory failure failure risk factors
  • 相关文献

参考文献2

二级参考文献18

  • 1Lettieri CJ,Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest ,2006,129:746-752.
  • 2Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest, 2007,131: 650-656.
  • 3Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticators in patients with idiopathic pulmonary fibrosis. Chest, 2007,131 : 650-656.
  • 4King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med,2001,164:1171-1181.
  • 5Barst R, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coil Cardiol, 2004,43:40-47.
  • 6Sztrymf B, Souza R, Bertoletti L, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J, 2010,35 : 1286 -1293.
  • 7Dentali F, Donadini M, Gianni M, et al. Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. Intern Emerg Med ,2009,4 : 123-128.
  • 8Leuchte H, Baumgartner R, Elnounou M, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med ,2006,173:744-750.
  • 9Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Ehest,2007,131:657-663.
  • 10Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in advanced sarcoidosis:epidemiology and clinical characteristics. Eur Respir J ,2005,25:783-788.

共引文献19

同被引文献48

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部